Can the combination of calcium and parathormone levels above k/doqi guidelines be used as a marker of adynamic bone disease in African Americans?

被引:2
作者
Diskin, Charles J. [1 ]
Stokes, Thomas J. [1 ]
Dansby, Linda M. [1 ]
Radcliff, Lautrec [1 ]
Carter, Thomas B. [1 ]
机构
[1] Auburn Univ, Hypertens Nephrol Dialysis & Transplantat Clin, Opelika, AL 36801 USA
关键词
Renal failure; Hemodialysis; Osteodystrophy; Racial differences; Parathormone; hypercalcemia; vitamin D; Bone resorption; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; C-PTH FRAGMENTS; PARATHYROID-HORMONE; SECONDARY HYPERPARATHYROIDISM; HEMODIALYSIS-PATIENTS; TURNOVER; FIBROBLAST-GROWTH-FACTOR-23; HOMEOSTASIS; PTH-(1-84);
D O I
10.1007/s11255-010-9785-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Patients of African American descent are at risk for the development of adynamic bone disease at parathyroid hormone levels 50% above the K/DOQI guidelines. Since a low bone formation rate is associated with hypercalcemia, attempts to reach one K/DOQI guideline may result in serum calcium levels above another K/DOQI guideline. Calcium levels above K/DOQI guidelines therefore may signal a need to stop parathyroid suppression. Bone biopsies were performed at the East Alabama Medical Center, in Opelika AL, USA on eight patients (four Caucasians, four African Americans) whose parathormone levels and serum calcium levels both exceeded K/DOQI guideline recommendations. All patients had mild to severe hyperparathyroid bone disease. No variable studied was predictive of the finding. Small sample size and the unavailability of the original Nichols Diagnostic Institute radioimmunoassay for parathormone. We did not find hypercalcemia predictive of adynamic bone in patients of African American descent at levels of parathormone where low bone formation rates have been documented to occur. Since no parameter predicted bone histology, perhaps bone biopsies will be necessary to distinguish hyperparathyroidism from adynamic bone disease in African Americans with ESRD, hypercalcemia, and moderately elevated levels of PTH. Further studies are needed to determine appropriate therapy.
引用
收藏
页码:1127 / 1132
页数:6
相关论文
共 37 条
[1]   Effects of vitamin D insufficiency on bone mineral density in African American men [J].
Akhter, N. ;
Sinnott, B. ;
Mahmood, K. ;
Rao, S. ;
Kukreja, S. ;
Barengolts, E. .
OSTEOPOROSIS INTERNATIONAL, 2009, 20 (05) :745-750
[2]  
Aloia John F, 2006, Endocr Pract, V12, P137
[3]  
[Anonymous], NKF K DOQI GUID K DO
[4]  
Arenas MD, 2007, J NEPHROL, V20, P453
[5]  
Ashman N, 2001, CLIN NEPHROL, V55, P327
[7]   Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism [J].
Brancaccio, Diego ;
Bonimerz, Juergen ;
Coyne, Daniel .
DRUGS, 2007, 67 (14) :1981-1998
[8]  
Buargub MA, 2006, SAUDI J KIDNEY DIS T, V17, P401
[9]   Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: Implication for treatment decisions [J].
Cantor, Tom ;
Yang, Zan ;
Caraiani, Nicolae ;
Ilamathi, Ekambaram .
CLINICAL CHEMISTRY, 2006, 52 (09) :1771-1776
[10]   PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease [J].
Coen, G ;
Bonucci, E ;
Ballanti, P ;
Balducci, A ;
Calabria, S ;
Nicolai, GA ;
Fischer, MS ;
Lifrieri, F ;
Manni, M ;
Morosetti, M ;
Moscaritolo, E ;
Sardella, D .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (02) :348-354